Smart albumin-loaded Rose Bengal and doxorubicin nanoparticles for breast cancer therapy

References

• Aggarwal, N. and Sloane, B.F., 2014. Cathepsin B: multiple roles in cancer. Proteomics. Clinical applications, 8(5–6), 427–437.
   PubMed Web of Science ®Google Scholar
• Agudelo, D., Bérubé, G., and Tajmir-Riahi, H.A., 2016. An overview on the delivery of antitumor drug doxorubicin by carrier proteins. International journal of biological macromolecules, 88, 354–360.
   PubMed Web of Science ®Google Scholar
• Cagel, M., et al., 2017. Doxorubicin: nanotechnological overviews from bench to bedside. Drug discovery today, 22(2), 270–281.
   PubMed Web of Science ®Google Scholar
• Cairns, R.A., Harris, I.S., and Mak, T.W., 2011. Regulation of cancer cell metabolism. Nature reviews. Cancer, 11(2), 85–95.
   PubMed Web of Science ®Google Scholar
• Carvalho, C., et al., 2009. Doxorubicin: the good, the bad and the ugly effect. Current medicinal chemistry, 16(25), 3267–3285.
   PubMed Web of Science ®Google Scholar
• Chen, Y., et al., 2017. Near-infrared light-mediated DOX-UCNPs@mHTiO2 nanocomposite for chemo/photodynamic therapy and imaging. Colloids and surfaces B: biointerfaces, 154, 429–437.
   PubMed Web of Science ®Google Scholar
• Dreis, S., et al., 2007. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. International journal of pharmaceutics, 341(1–2), 207–214.
   PubMed Web of Science ®Google Scholar
• Droge, W., 2002. Free radicals in the physiological control of cell function. Physiological reviews, 82, 47–95.
   PubMed Web of Science ®Google Scholar
• Gomez-Auli, A., et al., 2016. Impact of cathepsin B on the interstitial fluid proteome of murine breast cancers. Biochimie, 122, 88–98.
   PubMed Web of Science ®Google Scholar
• Gondi, C.S. and Rao, J.S., 2013. Cathepsin B as a cancer target. Expert opinion on therapeutic targets, 17(3), 281–291.
   PubMed Web of Science ®Google Scholar
• Harbeck, N. and Gnant, M., 2017. Breast cancer. Lancet (London, England), 389(10074), 1134–1150.
   PubMed Web of Science ®Google Scholar
• Hou, B., et al., 2017. Controlled co-release of doxorubicin and reactive oxygen species for synergistic therapy by NIR remote-triggered nanoimpellers. Materials science and engineering: C, 74, 94–102.
   PubMed Web of Science ®Google Scholar
• Huang, P., et al., 2014. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug–drug conjugate for cancer therapy. Journal of the American Chemical Society, 136(33), 11748–11756.
   PubMed Web of Science ®Google Scholar
• Ishibashi, O., et al., 1999. Breast cancer cells express cathepsins B and L but not cathepsins K or H. Cancer biochemistry biophysics, 17(1–2), 69–78.
   PubMedGoogle Scholar
• Karimi, M., et al., 2016. Albumin nanostructures as advanced drug delivery systems. Expert opinion on drug delivery, 13(11), 1609–1623.
   PubMed Web of Science ®Google Scholar
• Lian, H., et al., 2017. Self-assembled albumin nanoparticles for combination therapy in prostate cancer. International journal of nanomedicine, 12, 7777–7787.
   PubMed Web of Science ®Google Scholar
• Logan, K., et al., 2019. Targeted chemo-sonodynamic therapy treatment of breast tumours using ultrasound responsive microbubbles loaded with paclitaxel, doxorubicin and Rose Bengal. European journal of pharmaceutics and biopharmaceutics, 139, 224–231.
   PubMed Web of Science ®Google Scholar
• Ludke, A., et al., 2017. Time course of changes in oxidative stress and stress-induced proteins in cardiomyocytes exposed to doxorubicin and prevention by vitamin C. PLoS one, 12(7), e0179452.
   PubMed Web of Science ®Google Scholar
• Mitrovic, A., Pecar Fonovic, U., and Kos, J., 2017. Cysteine cathepsins B and X promote epithelial–mesenchymal transition of tumor cells. European journal of cell biology, 96, 622–631.
   PubMed Web of Science ®Google Scholar
• Nouh, M.A., et al., 2011. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. Journal of translational medicine, 9(1), 1.
   PubMedGoogle Scholar
• Peetla, C., et al., 2010. Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Molecular pharmaceutics, 7(6), 2334–2348.
   PubMed Web of Science ®Google Scholar
• Picos-Corrales, L.A., et al., 2019. NIPAAm-containing amphiphilic block copolymers with tailored LCST: aggregation behavior, cytotoxicity and evaluation as carriers of indomethacin, tetracycline and doxorubicin. Journal of macromolecular science, part A, 56(8), 759–772.
   Web of Science ®Google Scholar
• Qi, W.W., et al., 2015. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy. Molecular pharmaceutics, 12(3), 675–683.
   PubMed Web of Science ®Google Scholar
• Ramanathan, B., et al., 2005. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer research, 65(18), 8455–8460.
   PubMed Web of Science ®Google Scholar
• Sabri, T., Pawelek, P.D., and Capobianco, J.A., 2018. Dual activity of Rose Bengal functionalized to albumin-coated lanthanide-doped upconverting nanoparticles: targeting and photodynamic therapy. ACS applied materials & interfaces, 10(32), 26947–26953.
   PubMed Web of Science ®Google Scholar
• Shafei, A., et al., 2017. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomedicine & pharmacotherapy, 95, 1209–1218.
   PubMed Web of Science ®Google Scholar
• Shahzad, Y., et al., 2014. Bioactive albumin-based carriers for tumour chemotherapy. Current cancer drug targets, 14, 752–763.
   PubMed Web of Science ®Google Scholar
• Sharma, A., Jain, N., and Sareen, R., 2013. Nanocarriers for diagnosis and targeting of breast cancer. Biomed research international, 2013, 960821.
   PubMed Web of Science ®Google Scholar
• Shi, J., et al., 2017. A nanoliposome-based photoactivable drug delivery system for enhanced cancer therapy and overcoming treatment resistance. International journal of nanomedicine, 12, 8257–8275.
   PubMed Web of Science ®Google Scholar
• Su, Z., et al., 2014. ROS-triggered and regenerating anticancer nanosystem: an effective strategy to subdue tumor’s multidrug resistance. Journal of controlled release, 196, 370–383.
   PubMed Web of Science ®Google Scholar
• Sun, T., et al., 2016. Expression profile of cathepsins indicates the potential of cathepsins B and D as prognostic factors in breast cancer patients. Oncology letters, 11(1), 575–583.
   PubMed Web of Science ®Google Scholar
• Swisher, L.Z., et al., 2015. Quantitative electrochemical detection of cathepsin B activity in breast cancer cell lysates using carbon nanofiber nanoelectrode arrays toward identification of cancer formation. Nanomedicine, 11(7), 1695–1704.
   PubMed Web of Science ®Google Scholar
• Tezcaner, A., Baran, E.T., and Keskin, D., 2016. Nanoparticles based on plasma proteins for drug delivery applications. Current pharmaceutical design, 22(22), 3445–3454.
   PubMed Web of Science ®Google Scholar
• Trachootham, D., Alexandre, J., and Huang, P., 2009. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature reviews drug discovery, 8(7), 579–591.
   PubMed Web of Science ®Google Scholar
• Vanerio, N., et al., 2019. Biomedical applications of photo- and sono-activated Rose Bengal: a review. Photobiomodulation, photomedicine, and laser surgery, 7, 383–394.
   Google Scholar
• Wagner, S., et al., 2010. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials, 31(8), 2388–2398.
   PubMed Web of Science ®Google Scholar
• Wen, S.Y., et al., 2018. Diallyl trisulfide suppresses doxorubicin-induced cardiomyocyte apoptosis by inhibiting MAPK/NF-kappaB signaling through attenuation of ROS generation. Environmental toxicology, 33(1), 93–103.
   PubMed Web of Science ®Google Scholar
• Yeh, H.P., et al., 2018. A new photosensitized oxidation-responsive nanoplatform for controlled drug release and photodynamic cancer therapy. ACS applied materials & interfaces, 10(25), 21160–21172.
   PubMed Web of Science ®Google Scholar
• Zeng, L., et al., 2015. Doxorubicin-loaded NaYF4:Yb/Tm-TiO2 inorganic photosensitizers for NIR-triggered photodynamic therapy and enhanced chemotherapy in drug-resistant breast cancers. Biomaterials, 57, 93–106.
   PubMed Web of Science ®Google Scholar
• Zheng, K., et al., 2015. Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo. International journal of nanomedicine, 10, 5327–5342.
   PubMed Web of Science ®Google Scholar
• Zhou, G., et al., 2016. Optimal ROS signaling is critical for nuclear reprogramming. Cell reports, 15(5), 919–925.
   PubMed Web of Science ®Google Scholar
• Zhou, Z., et al., 2016. Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy. Chemical society reviews, 45(23), 6597–6626.
   PubMed Web of Science ®Google Scholar